The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rituximab Receives Label Update for ANCA-Associated Vasculitis

Rituximab Receives Label Update for ANCA-Associated Vasculitis

November 26, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In late October, the U.S. Food and Drug Administration approved an update for rituximab’s (Rituxan) label.1 The label will now include information about follow-up treatment in adults with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) who have achieved disease control with induction treatment. The change is based on results from the MAINRITSAN trial, which was a randomized, controlled clinical trial of rituximab conducted by the French Vasculitis Study Group.

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • ANCA-Associated Vasculitis Pathogenesis & Treatment Updates
Explore This Issue
December 2018
Also By This Author
  • FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved

In 2011, the FDA approved rituximab combined with glucocorticoids to treat adult patients with GPA and MPA, with the precaution that limited data were available on the safety and efficacy of subsequent courses in these patients. The safety and efficacy of rituximab retreatment had not yet been established.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

New Research
The MAINRITSAN trial evaluated the efficacy and safety of rituximab compared with azathioprine as follow-up treatment for ANCA-associated vasculitis, such as GPA and MPA. To participate, study patients (N=115; 86 with GPA, 24 with MPA, five with renal-limited ANCA-associated vasculitis) had to have achieved disease control after remission induction with cyclophosphamide and glucocorticoids. The follow-up regimen consisted of rituximab with glucocorticoids.

The study’s primary endpoint was the occurrence of major relapse by Month 28. The study defined major relapse as the reappearance of clinical and/or laboratory signs of vasculitis activity that could be life threatening or lead to organ failure or damage.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At Month 28, three patients (5%) on the rituximab regimen achieved the primary endpoint. By Month 28, 17 patients (29%) in the azathioprine-treated group achieved the primary endpoint.

As a result of this research, the label update will remove the precaution for GPA and MPA from rituximab’s prescribing information.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Genentech Inc. News release: FDA approves label update for Genentech’s Rituxan (rituximab) in two rare forms of vasculitis. 2018 Oct 19.
  2. U.S. Department of Health and Human Services. Letter: Supplemental BLA approval for rituximab. 2011 Apr 19.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: FDA, GPA, granulomatosis with polyangiitis, microscopic polyangiitis (MPA), U.S. Food and Drug Administration (FDA)Issue: December 2018

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • ANCA-Associated Vasculitis Pathogenesis & Treatment Updates
  • Maintenance of Remission in ANCA-Associated Vasculitis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)